Inventor
DALY CHRISTOPHER
US34 patents
⚠️ This page may combine multiple inventors who share the name “DALY CHRISTOPHER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
21 patentsUS9132192B2Sep 15, 2015
Anti-EGFR antibodies and uses thereof
REGENERON PHARMA72 citations98
US8980268B2Mar 17, 2015
Methods for treating cancer by administering an anti-Ang-2 antibody
REGENERON PHARMA16 citations92
US8791244B2Jul 29, 2014
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA12 citations92
US11142578B2Oct 12, 2021
Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
REGENERON PHARMA6 citations83
US9827310B2Nov 28, 2017
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA4 citations83
US9284380B2Mar 15, 2016
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA5 citations83
US10632194B2Apr 28, 2020
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA2 citations72
US9273143B2Mar 1, 2016
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
REGENERON PHARMA6 citations72
US12545735B2Feb 10, 2026
Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
REGENERON PHARMA0 citations62
US11866502B2Jan 9, 2024
Anti-FGFR2 antibodies and methods of use thereof
REGENERON PHARMA0 citations62
US11771762B2Oct 3, 2023
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA0 citations62
US12583939B2Mar 24, 2026
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
REGENERON PHARMA0 citations60
US11958910B2Apr 16, 2024
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
REGENERON PHARMA1 citations60
US12516323B2Jan 6, 2026
Methods and compositions for sensitization of tumor cells to immune therapy
REGENERON PHARMA0 citations58
US11965161B2Apr 23, 2024
Methods and compositions for sensitization of tumor cells to immune therapy
REGENERON PHARMA1 citations58
US10875911B2Dec 29, 2020
High affinity human antibodies to human angiopoietin-2
REGENERON PHARMA0 citations52
US10588940B2Mar 17, 2020
Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
REGENERON PHARMA0 citations52
US9938339B2Apr 10, 2018
Method for treating an eye disease or disorder by administering an antibody that binds angiopoietin-2
REGENERON PHARMA0 citations52
US9926369B2Mar 27, 2018
Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
REGENERON PHARMA0 citations52
US9789184B2Oct 17, 2017
Anti-EGFR antibodies and uses thereof
REGENERON PHARMA1 citations52
US9371379B2Jun 21, 2016
Methods for treating malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
REGENERON PHARMA1 citations46
JOHNSON MATTHEY PLC
7 patentsUS11845064B2Dec 19, 2023
Composite, zoned oxidation catalyst for a compression ignition internal combustion engine
JOHNSON MATTHEY PLC7 citations83
US10179325B2Jan 15, 2019
Exhaust system for a compression ignition engine having a capture region for volatilised platinum
JOHNSON MATTHEY PLC1 citations62
US12296319B2May 13, 2025
Composite, zoned oxidation catalys for a compression ignition internal combustion engine
JOHNSON MATTHEY PLC0 citations59
US10357743B2Jul 23, 2019
Oxidation catalyst for a diesel engine exhaust
JOHNSON MATTHEY PLC1 citations57
US12343714B2Jul 1, 2025
Composite, zoned oxidation catalyst for a compression ignition internal combustion engine
JOHNSON MATTHEY PLC0 citations49
US12318760B2Jun 3, 2025
Composite, zone-coated, dual-use ammonia (AMOX) and nitric oxide oxidation catalyst
JOHNSON MATTHEY PLC0 citations47
US11618014B2Apr 4, 2023
Method of coating a substrate with a particle stabilized foam
JOHNSON MATTHEY PLC0 citations45